Venus Medtech (Hangzhou) Inc. (HKG:2500)

Market Cap	1.03B -42.7%
Revenue (ttm)	468.17M -8.4%
Net Income	-704.14M
EPS	-1.61
Shares Out	437.90M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,349,500
Average Volume	1,076,475
Open	2.400
Previous Close	2.410
Day's Range	2.330 - 2.420
52-Week Range	1.590 - 5.470
Beta	1.12
RSI	33.13
Earnings Date	Mar 27, 2026

About Venus Medtech (Hangzhou)

Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat the patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Ve...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2009
• Employees: 605
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2500

Financial Performance

In 2024, Venus Medtech (Hangzhou)'s revenue was 470.83 million, a decrease of -4.18% compared to the previous year's 491.37 million. Losses were -714.31 million, 1.50% more than in 2023.

Financial numbers in CNY